Compare Ascendis Pharma A/S (ASND) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Public Storage — how do they compare? Ascendis Pharma A/S trades at $265.85 (market cap $17.74B), while Public Storage trades at $323.66 (market cap $56.28B). The key difference: Public Storage is far larger — about 3.2× Ascendis Pharma A/S's market cap, and Public Storage pays a 3.74% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PSA | |
|---|---|---|
Market Cap | $17.74B | $56.28B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $329.64 |
52-Week Low | $163.32 | $258.44 |
Enterprise Value | $18.11B | $70.53B |
Dividend Yield | — | 3.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Public Storage (PSA) trades at $320.56, up 0.38% with a bullish technical signal. The company demonstrates strong profitability with 39.16% net margins and consistent earnings beats. Recent developments include a $900 million note offering to fund the National Storage Affiliates acquisition and expansion into Canadian markets, signaling growth ambitions. Analyst consensus targets $332.25 with 65.72% hold ratings.
PSA offers stable income with recent dividend payments but faces execution risks from expansion initiatives. Valuation multiples appear elevated with P/E of 33.12, requiring sustained growth to justify premium pricing. The stock's near-term performance hinges on Q2 2026 earnings results due July 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
